肿瘤指南

订阅

MedSci主页 / 所有栏目 / 肿瘤指南

弥漫性大B细胞淋巴瘤诊疗指南 （2022年版）

2022-04-11 国家癌症中心 卫健委官网

弥漫性大B细胞淋巴瘤血液系统恶性肿瘤

弥漫性大 B 细胞淋巴瘤（diffuse large B cell lymphoma，DLBCL）是一种来源于成熟 B 细胞的侵袭性肿瘤，是最常见的非霍奇金淋巴瘤类型，约占全部非霍奇金淋巴瘤的 25%

中文标题：

弥漫性大B细胞淋巴瘤诊疗指南 （2022年版）

发布机构：

国家癌症中心

发布日期：

2022-04-11

简要介绍：

弥漫性大 B 细胞淋巴瘤（diffuse large B cell lymphoma，DLBCL）是一种来源于成熟 B 细胞的侵袭性肿瘤，是最常见的非霍奇金淋巴瘤类型，约占全部非霍奇金淋巴瘤的 25%～50%。

相关资料下载：
[AttachmentFileName(sort=1, fileName=弥漫性大B细胞淋巴瘤诊疗指南 （2022年版）.pdf)] GetToolGuiderByIdResponse(projectId=1, id=b94ed1c002a12496, title=弥漫性大B细胞淋巴瘤诊疗指南 （2022年版）, enTitle=, guiderFrom=卫健委官网, authorId=0, author=, summary=弥漫性大 B 细胞淋巴瘤（diffuse large B cell lymphoma，DLBCL）是一种来源于成熟 B 细胞的侵袭性肿瘤，是最常见的非霍奇金淋巴瘤类型，约占全部非霍奇金淋巴瘤的 25%, cover=https://img.medsci.cn/20220414/1649880893482_5579292.png, journalId=0, articlesId=null, associationId=1931, associationName=国家癌症中心, associationIntro=国家癌症中心, copyright=0, guiderPublishedTime=Mon Apr 11 00:00:00 CST 2022, originalUrl=, linkOutUrl=, content=<p><span style="color: #000000;">弥漫性大 B 细胞淋巴瘤（diffuse large B cell lymphoma，</span><span style="color: #000000;">DLBCL）是一种来源于成熟 B 细胞的侵袭性肿瘤，是最常见的非霍奇金淋巴瘤类型，约占全部非霍奇金淋巴瘤的 25%～50%。</span></p>, tagList=[TagDto(tagId=9536, tagName=弥漫性大B细胞淋巴瘤), TagDto(tagId=40191, tagName=血液系统恶性肿瘤)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤, tenant=100), CategoryDto(categoryId=21, categoryName=血液科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=7391, appHits=642, showAppHits=0, pcHits=2457, showPcHits=6748, likes=4, shares=113, comments=14, approvalStatus=1, publishedTime=Thu Apr 14 15:13:00 CST 2022, publishedTimeString=2022-04-11, pcVisible=1, appVisible=1, editorId=0, editor=FUNNYMAN, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=FUNNYMAN, createdTime=Thu Apr 14 04:17:07 CST 2022, updatedBy=5579292, updatedName=FUNNYMAN, updatedTime=Sat Jan 06 21:12:08 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=弥漫性大B细胞淋巴瘤诊疗指南 （2022年版）.pdf)])
弥漫性大B细胞淋巴瘤诊疗指南 （2022年版）.pdf
下载请点击：
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2159274, encodeId=794421592e4f8, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87a58859000, createdName=ms9000001112223673, createdTime=Sat Sep 23 13:03:40 CST 2023, time=2023-09-23, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2097988, encodeId=e70d209e98865, content=很好，感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=76e35503173, createdName=李子宁, createdTime=Wed Nov 02 07:31:33 CST 2022, time=2022-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1243288, encodeId=196512432888b, content=感谢分享~ , beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c18089343, createdName=xinxing, createdTime=Mon Sep 05 11:59:35 CST 2022, time=2022-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236161, encodeId=6adc1236161d5, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ebe35696751, createdName=ms8000001884414866, createdTime=Tue Aug 02 15:47:11 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1223250, encodeId=c8e7122325098, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210908/0a2513fcf13a40d0b7cefbf19efb116c/b9b7e818cc574d14a70c470375f4ccbd.jpg, createdBy=cc9f5598711, createdName=苏韵阑珊, createdTime=Sun May 29 22:43:51 CST 2022, time=2022-05-29, status=1, ipAttribution=)]
    2023-09-23 ms9000001112223673 来自广东省

    感谢分享

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2159274, encodeId=794421592e4f8, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87a58859000, createdName=ms9000001112223673, createdTime=Sat Sep 23 13:03:40 CST 2023, time=2023-09-23, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2097988, encodeId=e70d209e98865, content=很好，感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=76e35503173, createdName=李子宁, createdTime=Wed Nov 02 07:31:33 CST 2022, time=2022-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1243288, encodeId=196512432888b, content=感谢分享~ , beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c18089343, createdName=xinxing, createdTime=Mon Sep 05 11:59:35 CST 2022, time=2022-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236161, encodeId=6adc1236161d5, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ebe35696751, createdName=ms8000001884414866, createdTime=Tue Aug 02 15:47:11 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1223250, encodeId=c8e7122325098, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210908/0a2513fcf13a40d0b7cefbf19efb116c/b9b7e818cc574d14a70c470375f4ccbd.jpg, createdBy=cc9f5598711, createdName=苏韵阑珊, createdTime=Sun May 29 22:43:51 CST 2022, time=2022-05-29, status=1, ipAttribution=)]
    2022-11-02 李子宁

    很好，感谢分享

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2159274, encodeId=794421592e4f8, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87a58859000, createdName=ms9000001112223673, createdTime=Sat Sep 23 13:03:40 CST 2023, time=2023-09-23, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2097988, encodeId=e70d209e98865, content=很好，感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=76e35503173, createdName=李子宁, createdTime=Wed Nov 02 07:31:33 CST 2022, time=2022-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1243288, encodeId=196512432888b, content=感谢分享~ , beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c18089343, createdName=xinxing, createdTime=Mon Sep 05 11:59:35 CST 2022, time=2022-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236161, encodeId=6adc1236161d5, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ebe35696751, createdName=ms8000001884414866, createdTime=Tue Aug 02 15:47:11 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1223250, encodeId=c8e7122325098, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210908/0a2513fcf13a40d0b7cefbf19efb116c/b9b7e818cc574d14a70c470375f4ccbd.jpg, createdBy=cc9f5598711, createdName=苏韵阑珊, createdTime=Sun May 29 22:43:51 CST 2022, time=2022-05-29, status=1, ipAttribution=)]
    2022-09-05 xinxing

    感谢分享~

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2159274, encodeId=794421592e4f8, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87a58859000, createdName=ms9000001112223673, createdTime=Sat Sep 23 13:03:40 CST 2023, time=2023-09-23, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2097988, encodeId=e70d209e98865, content=很好，感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=76e35503173, createdName=李子宁, createdTime=Wed Nov 02 07:31:33 CST 2022, time=2022-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1243288, encodeId=196512432888b, content=感谢分享~ , beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c18089343, createdName=xinxing, createdTime=Mon Sep 05 11:59:35 CST 2022, time=2022-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236161, encodeId=6adc1236161d5, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ebe35696751, createdName=ms8000001884414866, createdTime=Tue Aug 02 15:47:11 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1223250, encodeId=c8e7122325098, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210908/0a2513fcf13a40d0b7cefbf19efb116c/b9b7e818cc574d14a70c470375f4ccbd.jpg, createdBy=cc9f5598711, createdName=苏韵阑珊, createdTime=Sun May 29 22:43:51 CST 2022, time=2022-05-29, status=1, ipAttribution=)]
    2022-08-02 ms8000001884414866

    感谢分享

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2159274, encodeId=794421592e4f8, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87a58859000, createdName=ms9000001112223673, createdTime=Sat Sep 23 13:03:40 CST 2023, time=2023-09-23, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2097988, encodeId=e70d209e98865, content=很好，感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=76e35503173, createdName=李子宁, createdTime=Wed Nov 02 07:31:33 CST 2022, time=2022-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1243288, encodeId=196512432888b, content=感谢分享~ , beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c18089343, createdName=xinxing, createdTime=Mon Sep 05 11:59:35 CST 2022, time=2022-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236161, encodeId=6adc1236161d5, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ebe35696751, createdName=ms8000001884414866, createdTime=Tue Aug 02 15:47:11 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1223250, encodeId=c8e7122325098, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210908/0a2513fcf13a40d0b7cefbf19efb116c/b9b7e818cc574d14a70c470375f4ccbd.jpg, createdBy=cc9f5598711, createdName=苏韵阑珊, createdTime=Sun May 29 22:43:51 CST 2022, time=2022-05-29, status=1, ipAttribution=)]
    2022-05-29 苏韵阑珊

    感谢分享

    0

以上为热门评论，梅斯医学App还有更多内容

相关指南

2018 ILROG指南：复发/难治性弥漫性大B细胞淋巴瘤患者放射治疗的作用

国际淋巴瘤放射学组(ILROG,International Lymphoma Radiation Oncology Group) · 2018-02-01

2016 ESMO临床实践指南：结外弥漫性大B细胞淋巴瘤（DLBCL）和原发性纵隔B细胞淋巴瘤的诊断，治疗和随访

欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology) · 2016-07-04

2016 BCSH指南：弥漫性大B细胞淋巴瘤的管理

英国血液学标准委员会(BCSH,British Committee for Standards in Haematology) · 2016-05-16